[SCHEDULE 13G/A] Unicycive Therapeutics, Inc. SEC Filing
Octagon Capital Advisors LP and related funds and principal Ting Jia report beneficial ownership of 1,000,000 shares of Unicycive Therapeutics, Inc. (UNCY), representing 7.8% of the outstanding common stock based on 12,768,239 shares outstanding as reported by the issuer. Octagon is the investment manager of the funds and Mr. Jia is the managing member of Octagon, and by virtue of those relationships Octagon and Mr. Jia may be deemed to beneficially own the shares held by the funds.
The filing discloses that the reported holdings are held with shared voting and dispositive power rather than sole power. The ownership is allocated as 650,000 shares (5.1%) held by Octagon Investments Master Fund LP and 350,000 shares (2.7%) held by Octagon Private Opportunities Fund II LP. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Octagon Capital Advisors LP e i fondi correlati e il principale Ting Jia segnalano la proprietà beneficiaria di 1,000,000 azioni di Unicycive Therapeutics, Inc. (UNCY), pari al 7.8% del capitale sociale ordinario in circolazione sulla base di 12,768,239 azioni in circolazione come riportato dall'emittente. Octagon è il gestore degli investimenti dei fondi e il sig. Jia è il membro amministratore di Octagon; in virtù di tali rapporti Octagon e il sig. Jia possono essere ritenuti beneficiari delle azioni detenute dai fondi.
Il deposito indica che le partecipazioni dichiarate sono detenute con potere di voto e di disposizione condivisi e non con potere esclusivo. La proprietà è ripartita in 650,000 azioni (5.1%) detenute da Octagon Investments Master Fund LP e 350,000 azioni (2.7%) detenute da Octagon Private Opportunities Fund II LP. Il deposito include una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attività e non allo scopo di modificare o influenzare il controllo dell'emittente.
Octagon Capital Advisors LP y los fondos relacionados y el principal Ting Jia comunican la titularidad beneficiaria de 1,000,000 acciones de Unicycive Therapeutics, Inc. (UNCY), lo que representa el 7.8% del capital social ordinario en circulación, según las 12,768,239 acciones en circulación reportadas por el emisor. Octagon es el administrador de inversiones de los fondos y el Sr. Jia es el miembro gerente de Octagon; en virtud de esas relaciones, Octagon y el Sr. Jia pueden considerarse beneficiarios de las acciones que poseen los fondos.
La presentación revela que las participaciones declaradas se mantienen con poder compartido de voto y de disposición y no con poder exclusivo. La propiedad se asigna como 650,000 acciones (5.1%) mantenidas por Octagon Investments Master Fund LP y 350,000 acciones (2.7%) mantenidas por Octagon Private Opportunities Fund II LP. La presentación incluye una certificación de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.
Octagon Capital Advisors LP 및 관련 펀드와 대표자 Ting Jia는 Unicycive Therapeutics, Inc. (UNCY)의 1,000,000주에 대한 수익적 소유권을 신고했으며, 이는 발행자가 보고한 12,768,239주의 발행주식 기준으로 유통 중인 보통주 가운데 7.8%에 해당합니다. Octagon은 해당 펀드들의 투자운용사이고 Jia 씨는 Octagon의 매니징 멤버로, 이러한 관계에 따라 Octagon과 Jia 씨는 펀드가 보유한 주식을 실질적 소유자로 간주될 수 있습니다.
신고서에는 신고된 보유주식이 단독 권한이 아닌 공동의 의결권 및 처분권으로 보유되어 있다고 명시되어 있습니다. 소유 지분은 Octagon Investments Master Fund LP가 보유한 650,000주(5.1%)와 Octagon Private Opportunities Fund II LP가 보유한 350,000주(2.7%)로 배분되어 있습니다. 신고서에는 해당 증권이 영업의 통상적인 범위에서 취득·보유되었으며 발행사의 지배권을 변경하거나 영향력을 행사할 목적으로 취득된 것이 아님을 인증하는 내용이 포함되어 있습니다.
Octagon Capital Advisors LP et des fonds associés ainsi que le principal Ting Jia déclarent la propriété bénéficiaire de 1,000,000 actions de Unicycive Therapeutics, Inc. (UNCY), représentant 7.8% du capital social ordinaire en circulation sur la base de 12,768,239 actions en circulation rapportées par l'émetteur. Octagon est le gestionnaire d'investissement des fonds et M. Jia est le membre directeur d'Octagon ; en vertu de ces relations, Octagon et M. Jia peuvent être considérés comme bénéficiant de la propriété des actions détenues par les fonds.
Le dépôt indique que les participations déclarées sont détenues avec un pouvoir de vote et de disposition partagé plutôt qu'un pouvoir exclusif. La détention se répartit comme suit : 650,000 actions (5.1%) détenues par Octagon Investments Master Fund LP et 350,000 actions (2.7%) détenues par Octagon Private Opportunities Fund II LP. Le dépôt inclut une certification selon laquelle les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur.
Octagon Capital Advisors LP und verbundene Fonds sowie der Principal Ting Jia melden wirtschaftliches Eigentum an 1,000,000 Aktien von Unicycive Therapeutics, Inc. (UNCY), was gemäß den vom Emittenten gemeldeten 12,768,239 ausstehenden Aktien 7.8% des ausstehenden Stammkapitals entspricht. Octagon ist der Investmentmanager der Fonds und Herr Jia ist geschäftsführendes Mitglied von Octagon; aufgrund dieser Beziehungen können Octagon und Herr Jia als wirtschaftliche Eigentümer der von den Fonds gehaltenen Aktien angesehen werden.
Die Einreichung legt offen, dass die gemeldeten Bestände mit gemeinsamen Stimm- und Verfügungsrechten und nicht mit alleinigem Recht gehalten werden. Die Beteiligung ist wie folgt aufgeteilt: 650,000 Aktien (5.1%) werden von Octagon Investments Master Fund LP gehalten und 350,000 Aktien (2.7%) werden von Octagon Private Opportunities Fund II LP gehalten. Die Einreichung enthält eine Bestätigung, dass die Wertpapiere im normalen Geschäftsverlauf erworben und gehalten wurden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten dienen.
- Material disclosure: A combined stake of 1,000,000 shares equals 7.8% of UNCY, exceeding the 5% reporting threshold.
- Clear allocation: Holdings are broken down by fund: 650,000 shares (5.1%) for the Master Fund and 350,000 shares (2.7%) for Private Fund II, improving transparency.
- No sole control: All reported voting and dispositive powers are shared (sole power reported as 0), indicating no direct control by the reporting persons.
- Held on behalf of investors: The funds hold the shares for their investors, meaning the economic interest is indirect rather than personal.
Insights
TL;DR Octagon and affiliates hold 7.8% of UNCY through funds, a material stake that signals investor interest but not control.
The Schedule 13G/A shows a combined beneficial ownership of 1,000,000 shares, equal to 7.8% of the outstanding common stock based on 12,768,239 shares. The reporting structure is fund-centric: 650,000 shares are held by the Master Fund and 350,000 by Private Fund II, with Octagon acting as investment manager and Mr. Jia as managing member. All voting and dispositive powers disclosed are shared rather than sole, which means the position is meaningful but does not convey direct control. The filing also affirms acquisition in the ordinary course of business.
TL;DR A >5% aggregated holding is reportable and material; governance impact appears limited because power is shared and not sole.
The document identifies joint filing by Octagon entities and Ting Jia and discloses shared voting and dispositive power for the reported positions. Because the reporting persons disclaim sole voting power, the stake is significant under disclosure rules but does not indicate an expressed intent to change board composition or control. The certification attesting ordinary-course acquisition further supports a passive, disclosure-driven filing rather than an activist posture.
Octagon Capital Advisors LP e i fondi correlati e il principale Ting Jia segnalano la proprietà beneficiaria di 1,000,000 azioni di Unicycive Therapeutics, Inc. (UNCY), pari al 7.8% del capitale sociale ordinario in circolazione sulla base di 12,768,239 azioni in circolazione come riportato dall'emittente. Octagon è il gestore degli investimenti dei fondi e il sig. Jia è il membro amministratore di Octagon; in virtù di tali rapporti Octagon e il sig. Jia possono essere ritenuti beneficiari delle azioni detenute dai fondi.
Il deposito indica che le partecipazioni dichiarate sono detenute con potere di voto e di disposizione condivisi e non con potere esclusivo. La proprietà è ripartita in 650,000 azioni (5.1%) detenute da Octagon Investments Master Fund LP e 350,000 azioni (2.7%) detenute da Octagon Private Opportunities Fund II LP. Il deposito include una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attività e non allo scopo di modificare o influenzare il controllo dell'emittente.
Octagon Capital Advisors LP y los fondos relacionados y el principal Ting Jia comunican la titularidad beneficiaria de 1,000,000 acciones de Unicycive Therapeutics, Inc. (UNCY), lo que representa el 7.8% del capital social ordinario en circulación, según las 12,768,239 acciones en circulación reportadas por el emisor. Octagon es el administrador de inversiones de los fondos y el Sr. Jia es el miembro gerente de Octagon; en virtud de esas relaciones, Octagon y el Sr. Jia pueden considerarse beneficiarios de las acciones que poseen los fondos.
La presentación revela que las participaciones declaradas se mantienen con poder compartido de voto y de disposición y no con poder exclusivo. La propiedad se asigna como 650,000 acciones (5.1%) mantenidas por Octagon Investments Master Fund LP y 350,000 acciones (2.7%) mantenidas por Octagon Private Opportunities Fund II LP. La presentación incluye una certificación de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.
Octagon Capital Advisors LP 및 관련 펀드와 대표자 Ting Jia는 Unicycive Therapeutics, Inc. (UNCY)의 1,000,000주에 대한 수익적 소유권을 신고했으며, 이는 발행자가 보고한 12,768,239주의 발행주식 기준으로 유통 중인 보통주 가운데 7.8%에 해당합니다. Octagon은 해당 펀드들의 투자운용사이고 Jia 씨는 Octagon의 매니징 멤버로, 이러한 관계에 따라 Octagon과 Jia 씨는 펀드가 보유한 주식을 실질적 소유자로 간주될 수 있습니다.
신고서에는 신고된 보유주식이 단독 권한이 아닌 공동의 의결권 및 처분권으로 보유되어 있다고 명시되어 있습니다. 소유 지분은 Octagon Investments Master Fund LP가 보유한 650,000주(5.1%)와 Octagon Private Opportunities Fund II LP가 보유한 350,000주(2.7%)로 배분되어 있습니다. 신고서에는 해당 증권이 영업의 통상적인 범위에서 취득·보유되었으며 발행사의 지배권을 변경하거나 영향력을 행사할 목적으로 취득된 것이 아님을 인증하는 내용이 포함되어 있습니다.
Octagon Capital Advisors LP et des fonds associés ainsi que le principal Ting Jia déclarent la propriété bénéficiaire de 1,000,000 actions de Unicycive Therapeutics, Inc. (UNCY), représentant 7.8% du capital social ordinaire en circulation sur la base de 12,768,239 actions en circulation rapportées par l'émetteur. Octagon est le gestionnaire d'investissement des fonds et M. Jia est le membre directeur d'Octagon ; en vertu de ces relations, Octagon et M. Jia peuvent être considérés comme bénéficiant de la propriété des actions détenues par les fonds.
Le dépôt indique que les participations déclarées sont détenues avec un pouvoir de vote et de disposition partagé plutôt qu'un pouvoir exclusif. La détention se répartit comme suit : 650,000 actions (5.1%) détenues par Octagon Investments Master Fund LP et 350,000 actions (2.7%) détenues par Octagon Private Opportunities Fund II LP. Le dépôt inclut une certification selon laquelle les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur.
Octagon Capital Advisors LP und verbundene Fonds sowie der Principal Ting Jia melden wirtschaftliches Eigentum an 1,000,000 Aktien von Unicycive Therapeutics, Inc. (UNCY), was gemäß den vom Emittenten gemeldeten 12,768,239 ausstehenden Aktien 7.8% des ausstehenden Stammkapitals entspricht. Octagon ist der Investmentmanager der Fonds und Herr Jia ist geschäftsführendes Mitglied von Octagon; aufgrund dieser Beziehungen können Octagon und Herr Jia als wirtschaftliche Eigentümer der von den Fonds gehaltenen Aktien angesehen werden.
Die Einreichung legt offen, dass die gemeldeten Bestände mit gemeinsamen Stimm- und Verfügungsrechten und nicht mit alleinigem Recht gehalten werden. Die Beteiligung ist wie folgt aufgeteilt: 650,000 Aktien (5.1%) werden von Octagon Investments Master Fund LP gehalten und 350,000 Aktien (2.7%) werden von Octagon Private Opportunities Fund II LP gehalten. Die Einreichung enthält eine Bestätigung, dass die Wertpapiere im normalen Geschäftsverlauf erworben und gehalten wurden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten dienen.